FDA clarifies the line between wellness and regulated medical devices
By Brian Dolan
January 16, 2015
Investor Business Daily
Fitbit fad concern 'overblown'; stock rebounds
BY PATRICK SEITZ
A final analysis of the SUPPRESS trial results is ongoing and will be presented at the BMT Tandem Meetings
in Honolulu, Hawaii, to be held on February 18-22, 2016 at BMT Meetings
wait until the wrongful deaths lawsuits, FIT done for. Thanks for the heads up!
JP Morgan Invested Money Into SUNE, If Anyone Going To Check The Books It's JP Morgan
The Fly On The Wall
Netflix analyst commentary at Cantor
Netflix price target raised to $140 from $125 at Cantor. Cantor raised its price target on Netflix after the company reported Q4 results that Cantor views as solid. The firm says that the company's guidance and its international subscriber growth were "impressive"
Mobihealth News- Mayo Clinic
Cedars Sinai to use Fitbits in small trial of cancer patients - Mayo Clinic